APONTIS PHARMA AG / DE000A3CMGM5
05.03.2025 - 20:50:29APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG – merger agreement planned
| EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out 05-March-2025 / 20:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 Monheim / Rhein, 5 March 2025. Zentiva AG today submitted a formal request to APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) pursuant to Sections 62 para.1 and para. 5 UmwG (German Transformation Act) in conjunction with Sections 327a et seq. AktG (German Stock Corporation Act), according to which a merger agreement is to be concluded between the Company and Zentiva, and the Annual General Meeting of APONTIS PHARMA AG is to resolve on the transfer of the shares of the remaining shareholders (minority shareholders) to Zentiva as the majority shareholder in return for an appropriate cash compensation (so-called squeeze-out under merger law). Zentiva has informed APONTIS PHARMA that it holds approximately 93.83% of the Company’s share capital after deduction of the number of treasury shares of APONTIS PHARMA (170,000 shares) in accordance with Section 62 para. 1 sentence 2 UmwG. As a result, Zentiva is the majority shareholder of APONTIS PHARMA within the meaning of Section 62 (5) UmwG in conjunction with Section 327a (1) AktG. The amount of the appropriate cash compensation that Zentiva will grant to the remaining shareholders of the Company for the transfer of the shares will be announced by Zentiva at a later date. APONTIS PHARMA will provide information about the date of the Annual General Meeting at which a corresponding transfer resolution is to be passed in accordance with the statutory requirements. Zentiva has proposed the commencement of negotiations on a merger agreement between Zentiva and APONTIS PHARMA. APONTIS PHARMA AG Investor Relations ir@apontis-pharma.de T: +49 2173 89 55 4900 F: +49 2173 89 55 1521 Alfred-Nobel-Str. 10 40789 Monheim / Rhein Germany apontis-pharma.de APONTIS PHARMA press contact CROSS ALLIANCE communication GmbH Sven Pauly ir@apontis-pharma.de T: +49 89 125 09 0330 End of Inside Information 05-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Rolf-Schwarz-Schütte-Platz 1 | |
| 40789 Monheim am Rhein | |
| Germany | |
| E-mail: | ir@apontis-pharma.de |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096063 |
| End of Announcement | EQS News Service |
| |
2096063 05-March-2025 CET/CEST
